Franklin Lakes, NJ, United States
Franklin Lakes, NJ, United States

Time filter

Source Type

- 409 MILLION GLUCOSE MEASUREMENTS FROM MORE THAN 50,000 FREESTYLE LIBRE USERS IN EUROPE SHOW PEOPLE MONITORED THEIR GLUCOSE LEVELS ON AVERAGE 16 TIMES PER DAY - 86 MILLION HOURS OF MONITORING DEMONSTRATE THAT A HIGHER NUMBER OF FREESTYLE LIBRE SCANS IS ASSOCIATED WITH BETTER DIABETES OUTCOMES INCLUDING A REDUCTION IN HYPOGLYCEMIA PARIS, Feb. 16, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the results of real-world use data[1] showing that people who scan more frequently using Abbott′s FreeStyle® Libre system spend less time in hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) while having improved average glucose levels. According to the data, more than 50,000 people with diabetes using the FreeStyle Libre system checked their glucose levels an average of 16 times per day—which is three times more than the minimum recommended U.S.[2] and European[3] guidelines for testing with the traditional fingerstick technique. The data show that higher rates of scanning with the FreeStyle Libre system were found to be strongly associated with improved glucose control. "There is now substantial evidence from both real-world usage and clinical studies that reaffirms the powerful impact of FreeStyle Libre," said Jared Watkin, senior vice president, Diabetes Care, Abbott. "FreeStyle Libre is changing how diabetes has been managed for decades, with one simple swipe. Most importantly, we're doing that by empowering patients with the information that they need to take action themselves, helping people living with diabetes live fuller, healthier lives." Abbott′s FreeStyle Libre system consists of a small, round sensor worn on the back of the upper arm for up to 14 days, which measures glucose every minute in interstitial fluid through a small filament that is inserted just under the skin and held in place with a small adhesive pad. A reader is scanned over the sensor to get a glucose result painlessly[4] in less than one second. The real-world data findings were presented today at the Advanced Technologies and Treatment for Diabetes (ATTD) congress in Paris. The data show a strong link between real-world use of FreeStyle Libre system and glucose control. The full data set was generated from 50,831 readers, which were used to scan 279,446 sensors. This constituted 409.4 million glucose measurements, 86.4 million monitoring hours and 63.8 million scans – representing more than 50,000 FreeStyle Libre users across the Europe region. Key findings of the real-world data of the FreeStyle Libre system: Empowering Patients with Actionable Information According to a published report in Patient Preference and Adherence[5] people test with traditional self-monitoring methods (pricking a finger with a lancet to get a blood sample) less than three times per day, which falls short of U.S.[2] and European[3] guidelines that recommend four to eight self-tests per day. People with diabetes cite the biggest obstacle to more frequent monitoring is the pain and hassle of routine fingersticks[5]. But when people with diabetes don't have a clear picture of their glucose levels from regular monitoring, complications such as hypoglycemia can become life-threatening and require hospitalization, which can lead to a significant increase in healthcare costs. Abbott's FreeStyle Libre system, which was introduced in Europe in 2014, removes the need for routine fingersticks[6],[7] — and the pain and hassles that come along with them[8]. In addition, FreeStyle Libre system is factory calibrated—meaning that it does not require a fingerstick test for calibration (a test requiring a blood sample to reset a system's accuracy) unlike other continuous glucose monitoring systems, which require two or more fingersticks per day to remain accurate. "My experience with FreeStyle Libre through daily clinical practice and research studies has been very positive," says Ramzi Ajjan, M.D., University of Leeds, U.K. "Patients report that the system helped them gain a better understanding of their glycaemia by enabling multiple daily glucose checks discreetly and conveniently. The system's painless nature of glucose testing are praised by patients with one commenting to me, 'you saved my fingers.' The real-world data further confirms that patients are checking glucose more frequently, up to 16 times per day on average, which is cumbersome to maintain with the conventional fingerstick method. With comprehensive glucose data, patients now have access to more meaningful information key for optimizing their glycaemia control." Real-World Usage Supports Randomized Controlled Data of FreeStyle Libre The new real-world data presented at ATTD further support the conclusions of the randomized controlled clinical studies conducted by Abbott with the FreeStyle Libre system including the IMPACT study[9] published in The Lancet in September 2016. In 2014, Abbott launched the FreeStyle Libre system in several countries in Europe. Currently, FreeStyle Libre system is available in more than 30 countries around the globe and is being used by more than 250,000 people living with diabetes. In the U.S., the FreeStyle Libre system is currently under review by the U.S. Food and Drug Administration[10]. About the Data De-identified data was collected over a period of 18 months when FreeStyle Libre readers were connected to the PC-based software with an active internet connection. All information was aggregated. No personal data was utilized or shared. About Abbott′s FreeStyle Libre System Abbott′s FreeStyle Libre system consists of a small, round sensor—approximately the size of two stacked U.S. quarters—worn on the back of the upper arm for up to 14 days, which measures glucose every minute in interstitial fluid through a small (5mm long, 0.4mm wide) filament that is inserted just under the skin and held in place with a small adhesive pad. A reader is scanned over the sensor to get a glucose result painlessly[4] in less than one second. Each scan displays a real-time glucose result, a historical trend and the direction the glucose is heading. The FreeStyle Libre system generates an Ambulatory Glucose Profile (AGP) that provides a visual snapshot of glucose levels, trends and patterns over time. About Abbott: At Abbott, we're committed to helping people live their best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve. Connect with us at www.abbott.com, on Facebook at www.facebook.com/Abbott and on Twitter @FreeStyleDiabet, @AbbottNews and @AbbottGlobal.


BOSTON--(BUSINESS WIRE)--T1D Exchange, a nonprofit organization accelerating research to improve outcomes in type 1 diabetes, today published a major research study in Diabetes Care that confirms the use of Continuous Glucose Monitoring (CGM) without regular use of confirmatory Blood Glucose Measurements (BGM) is safe and effective. For years, patients with type 1 diabetes have relied on blood glucose monitoring (BGM), widely known as the finger prick method, to measure their blood glucose levels many times each day and make insulin dosing decisions based on this information. CGM monitors are small wearable devices that automatically capture real-time glucose measures via a sensor that is inserted under the skin and transmits the information wirelessly to a monitoring and display device. CGM systems can detect and alert patients when they may be at risk of hyperglycemia (high blood glucose) or hypoglycemia (low blood glucose), both of which require intervention to avoid more dangerous complications. Over the past few years, adoption of CGM to monitor blood glucose levels has widely grown, according to T1D Exchange’s Clinical Registry which has health data on 32,000 patients with type 1 diabetes. Specifically, adoption of CGM in the registry cohort has grown from 7% CGM use overall (in analysis completed in 2010-2012) to 21% CGM use overall (in analysis completed during 2014-2015). The T1D Exchange Replace-BG research study was conceived to better understand how CGM systems are used by patients, how they affect their health outcomes and to build evidence that will be required to support access to and reimbursement of CGM systems. This research is also critical to advance the field of automated insulin delivery. Automated insulin delivery (AID), commonly referred to the “artificial pancreas,” is the evolution of current diabetes management devices to an integrated system incorporating insulin pumps, algorithms and CGM technology that will allow insulin delivery with little or no input from the patient – thereby relieving a significant burden while improving outcomes. As the first major study of its kind, T1D Exchange coordinated the multi-center study through its clinic network and enrolled 226 adults with type 1 diabetes. All study participants were provided with a Dexcom’s G4 Continuous Glucose Monitoring System with an enhanced algorithm, which was used for the 6-month duration of the study. Participants were split into two study arms: 149 participants dosed their insulin based on the CGM reading alone without first confirming with a blood glucose meter measurement and 77 were required to confirm the CGM reading with a blood glucose measurement before dosing insulin. Among the major findings of the study is the confirmation there was no difference in outcomes for those using only CGM and those using both CGM and BGM. “This study is an important step to support regulatory pathways for the automation of insulin delivery for people with type 1 diabetes,” says Dana Ball, executive director and co-founder of T1D Exchange. “These data are supportive of the recent FDA decision to approve the Dexcom G5 indication for insulin dosing and removes a key obstacle that has prevented reimbursement of CGM by Medicare.” "We are grateful that organizations such as T1D Exchange recognize the need to build evidence around the safety and efficacy of CGM use in treatment decisions,” says Kevin Sayer, president and chief executive officer of Dexcom. “We hope results from this study and the recent FDA decision to expand the indication of the Dexcom G5 system will diminish the hassle and pain of finger stick testing and expand access to CGM technology—ultimately leading to improved control for people with diabetes." This study was funded by The Leona M. and Harry B. Helmsley Charitable Trust and CGMs were donated by Dexcom. The research is being presented today at Advanced Technologies and Treatments for Diabetes (ATTD) in Paris, France by principal investigators from the Jaeb Center for Health Research in Tampa, FL, Katrina J. Ruedy, MSPH, and Roy W. Beck M.D., Ph.D., Director, T1D Exchange Clinic Coordinating Center. “As a practicing endocrinologist, I typically advise my patients who use CGM technology to make treatment decisions based on a BGM reading; however, many of my patients often use CGM readings to make decisions about insulin doses,” stated Grazia Aleppo, MD, Northwestern University and lead author of the study. “The results of this study assures clinicians that patients using CGM for treatment decisions is as safe and effective as BGM.” About T1D Exchange T1D Exchange was founded on the belief that people affected by type 1 diabetes need better solutions faster – better treatments and better care. Our nonprofit organization takes an innovative approach that puts the community of people touched by type 1 diabetes at the center of research that will meaningfully impact their lives. Our integrated model offers researchers access to aggregated clinical, biological, patient-reported outcomes and electronic health record data, all while fostering collaboration among patients, physicians, researchers and industry. Our model is multi-faceted and complex, but our goal is simple: to tangibly improve outcomes for people with type 1 diabetes as fast as humanly possible.


Research and Markets has announced the addition of the "Infusion Pumps - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. This report analyzes the worldwide markets for Infusion Pumps in US$ by the following Product Segments: The report profiles 52 companies including many key and niche players such as: - Infusion Pumps: An Alternate Drug Delivery Option - Current and Future Analysis - Developed Economies Dominate Infusion Pumps Market - Asia-Pacific: The Fastest Growing Market for Infusion Pumps - Analysis by Product Segments - Ambulatory Infusion Pumps - Enteral Feeding Pumps - Insulin Infusion Pumps - Large Volume Infusion Pumps - PCA Infusion Pumps - Syringe Infusion Pumps - Infusion Errors & Technology Defenses Developed Over the Years - Rise in Incidence of Chronic Diseases Fuels Infusion Pumps Demand - The Diabetes Epidemic - Untapped Potential for Insulin Pumps - Global Diabetes Expenditure: Opportunity Indicator for Insulin Pumps Market - Cancer Pain Offers Potential Opportunities for Pain Management Pumps - Infusion Pumps - A Highly Consolidated Market - Insulin Pumps Market - Competition Intensifies - Comparison of Select Durable Insulin Pumps by Manufacturer - Medtronic Banks on New Solutions and Distribution Expansion to Retain Dominance - J&J's OneTouch Via - A Discrete Solution for On-Demand Insulin - Ypsomed Eyes Brighter Prospects with YpsoPump - Medtrum - A New Entrant with a Strong Product; Threatening to Take the Market by Storm - Competitive Landscape in the Insulin Patch Pump Market - OmniPod Benefits from Lack of Close Competition in its League - Insulet Focuses on Advances in Technology and Services to Gain Market Share - Cellnovo's Patch Pump Combines Functionality and Cost- Effectiveness - V-Go - An Affordable Patch Pump for Type II Diabetics - Expiry of Warranty Provides New Opportunities to Insulin Pump Makers - Customer Satisfaction: Crucial to Stay Competitive - Enteral Feeding Devices: An Intensely Competitive Market - Multinationals Target Emerging Markets - The New Hotspots for Growth - Infusion Errors: A Key Driving Force for Newer Technologies - Manufacturers Focus on Interoperability with EMR Systems - Security of Wireless Medical Device - A Vital Factor - Shift from Hospital Environments to Alternative-Sites/ Home Settings Drives the market for Home Infusion Pumps - Product Complexity Thwarts ROI on Devices - Smart Pump Technology: A Major Growth Driver - Smart Pumps with Innovative Features - Improving Functionality for Enhanced Patient Compliance - Maintaining Smartness Quotient of Smart Infusion Pumps - Product Bundling: A Double Whammy Success - Analgesia Infusion Pumps Continue to Register Favorable Growth - Disposable Ambulatory Infusion Pumps Market Exhibits Notable Stride Forward - Enteral Feeding Pumps Market Overview - Replacements Offer Potential Growth Opportunities - Preference for Enteral Nutrition over Parenteral Nutrition Bodes Well - Advantages and Disadvantages of Enteral Nutrition over Parenteral Nutrition - Enteral Nutrition Therapy in Treating Adult Malnutrition Offers Growth Opportunities - Home Enteral Therapy to Boost Demand for Enteral Feeding Devices - Insulin Pumps - Designed for Optimum Disease Management - The Rise of Smart Pumps - Manufacturers Eye Type II Diabetes Market - Implantable Insulin Pumps - The Next Generation of Insulin Pumps - Patch Pumps Gain Manufacturer Attention - Insulin Pump Training - An Important Driver - Complicated Insulin Pump Software Makes Pump Use Difficult for the Aged - Competition from Other Insulin Delivery Technologies Continues - Maturity Hits Volumetric Infusion Pumps Market - Equipment Recalls Thwarts Growth Prospects - Stringent Safety Regulations Impede Time-to-Market - Look into Select Technology Advancements - Ivenix Develops Next-Generation Infusion Management Platform - Innovfusion Develops Advanced Infusion Pumps to Provide Relief from Labor Pain - Summit Medical's Low-Cost Portable Infusion Pumps Improve Patient Care - Product Malfunctioning Erodes Penetration of Implantable Infusion Pumps Rise in Healthcare Spending in Developing Nations Bode Well for the Market Aging Population: A Strong Growth Driver Global Aging Population Statistics Opportunity Indicators Rise in Incidence of Cancer and Central Nervous System Diseases Foster Growth World Cancer Statistics: Incidence and Mortality Data Diabetes Incidence and Prevalence Global Diabetic Statistics Opportunity Indicators Alarming Rise in Obesity A Business Case for Diabetes Care Rise in HIV Prevalence Provides Ample Growth Opportunities Global HIV Statistics Opportunity Indicators for Enteral Feeding Devices - FDA Announces Initiative to Address Safety Concerns Related to Infusion Pumps - FDA Announces a New Mandate for Manufacturing Companies - Regulations Promote Adoption of Premium-Priced Safety Devices - ISO 80369 Standards for Small-Bore Connector - ENFit - The New ISO Standard Enteral Feeding Connecting System - Infusion Pumps: A Definition - Types of Infusion Pumps - Ambulatory Infusion Pumps - Non-Electronic Ambulatory Infusion Pumps - Advantages & Disadvantages of Non-Electronic Pumps - Electronic Ambulatory Infusion Pumps - Nerve Block Infusion Pumps - Enteral Feeding Pumps - Insulin Infusion Pumps - Large Volume Infusion Pumps - Pump Architecture of Volumetric Pumps - Classification by End-Use Application - Volumetric Pumps used in Acute Care Settings - Volumetric Pumps used in Alternate Care Settings - Patient Controlled Analgesic (PCA) Pumps - Syringe Infusion Pumps - Low-End and High-End Syringe Pumps - Implantable Infusion Pumps - Programmable Implantable Infusion Pumps - Constant Flow Implantable Infusion Pumps - Approved Applications of Implantable Infusion Pumps - Common Safety Features Available In Most Infusion Pumps - Key Problems Reported with Infusion Pumps - User Interface Issues - Software Issues - Alarm Errors - Damaged Components - Battery Failures - Fire, Shocks, Sparks or Charring - Intelligraphics Enters into Collaboration with Ivenixto Develop Intelligent Infusion Pump Platform - Smiths Medical Introduces New Software Version for use with Medfusion® 4000 wireless syringe pumps - Caesarea Medical Announces Launch of its latest Dual Channel Infusion Pump - Medtronic Launches MiniMed® 630G System - Hospira Introduces LifeCare PCA 7.0 infusion pump with EMR Connectivity - Smiths Medical Launches New CADD®-Solis Pump - Animas Bags FDA Approval for Animas® Vibe® Insulin Pump and Continuous Glucose Monitoring System - Medtronic Rolls Out MiniMed 640G Insulin Pump - B. Braun Medical Secures FDA Approval for Infusomat® Space Pump - Zyno Medical Gains CE Mark Approval for Z-800 Infusion Pump System - Hospira Receives FDA Clearance for Plum 360 Infusion System - BioLeonhardt Develops Stem Cell Pump - Animas Rolls Out Animas® Vibe Insulin Pump with Latest Dexcom CGM Technology - Baxter Gets FDA Clearance for SIGMA Spectrum Infusion Pump with Master Drug Library - Animas Bags CE Mark Approval for Animas® Vibe Insulin Pump and Dexcom G4 PLATINUM CGM System - Animas Secures FDA Approval for Animas® Vibe Insulin Pump and Continuous Glucose Monitoring System Omnicell and Hospira Collaborate for System Interoperability BD Enters into Collaboration with JDRF to Develop Extended Wear Innovations for Insulin Infusion Delivery Teleflex Signs Group Purchasing Agreement with Premier Inc. for Implantable Infusion Ports ICU Medical to Acquire Pfizer's Infusion Therapy Business Zyno Medical Receives FDA 510(k) Clearance for Nimbus II Ambulatory Infusion System InfuSystem to Acquire Infusion Pump Assets from InfusAID, LLC Medtronic to Manufacture and Deploy Advanced Diabetes Therapies in Chengdu, China Pfizer Considers Sale of the Infusion Pump Business Pfizer Acquires Hospira InfuSystem Completes Acquisition of Ciscura Becton Dickinson Takes Over CareFusion Hospira Inks Agreement with Cerner for Developing Infusion Pump Information Platform Animas Partners with Tidepool Medtronic Partners with BD to Develop New Insulin Pump with BD FlowSmart Technology Fresenius Kabi Inks Agreement with Amerinet Hospira Faces Class I Recall of GemStar Infusion System - Animas Corporation (USA) - Baxter International Inc. (USA) - B. Braun Melsungen AG (Germany) - Becton, Dickinson and Company (USA) - F. Hoffmann-La Roche Ltd. (Switzerland) - Fresenius SE & Co. KGaA (Germany) - Halyard Health, Inc. (USA) - Hospira, Inc. (USA) - ICU Medical, Inc. (USA) - Insulet Corporation (USA) - Medtronic, PLC (Ireland) - Moog, Inc. (USA) - Smiths Medical (USA) - Sooil Development Co. Ltd. (Korea) - Tandem Diabetes Care, Inc. (USA) - Teleflex Incorporated (USA) - Terumo Corporation (Japan) - The United States - Japan - Europe - France - Germany - The United Kingdom - Rest of Europe - Asia-Pacific (Excluding Japan) - Middle East - Latin America For more information about this report visit http://www.researchandmarkets.com/research/cq3cv2/infusion_pumps


- Users of the mySugr app will be able to automatically upload blood glucose data from the next-generation Accu-Chek blood glucose meters, the Accu-Chek Guide and Accu-Chek Instant systems. - Users will benefit from enhanced capabilities  to share diabetes data with their healthcare providers and caregivers. - Healthcare providers can utilise existing Roche tools to make better therapy decisions in less time and improve their collaboration with patients who are users of the mySugr app. BASEL, Switzerland, Feb. 15, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the expansion of its partnership with mySugr, a digital diabetes service company providing apps to help reduce the burden for people with diabetes in managing their chronic condition. The integration of Roche's next generation of Accu-Chek blood glucose meters, the Accu-Chek Guide and the Accu-Chek Instant systems with the mySugr app allows users to benefit from the partnership in different ways: The ability to automatically upload blood glucose data into the mySugr app as well as the facilitated data sharing with healthcare professionals and caregivers via the cloud-based Accu-Chek Connect Online and emminens eConecta platforms. The partnership with mySugr supports both companies in broadening access to innovative digital health solutions. "With this expanded partnership we will continue to offer latest innovations to our customers that will empower them to seamlessly integrate therapy management into their everyday lives, so they have less to think and worry about," states Marcel Gmuender, Global Head of Roche Diabetes Care. "Digital health solutions have proven to help manage diabetes-related data more effectively. This makes data more meaningful1 and can ultimately lead to better therapy outcomes." The expanded agreement is effective as of today. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. About Roche Diabetes Care Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients' condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – leading to an improved medical outcome. For more information please visit www.accu-chek.com All trademarks used or mentioned in this release are protected by law. References 1. Hinnen D, Buskirk A, Lyden M, Amstutz L, Hunter T, Parkin CG, Wagner R. Use of diabetes data management software reports by health care providers, patients with diabetes, and caregivers improves accuracy and efficiency of data analysis and interpretation compared with traditional logbook data: first results from the Accu-Chek Connect Reports Utility and Efficiency Study (ACCRUES). J Diabetes Sci Technol. Pub online 2 Nov 2014. DOI: 10.1177/1932296814557188.


- Roche Diabetes Care will develop a special Bluetooth Low Energy (BLE) enabled blood glucose meter based on the new Accu-Chek Guide platform. - This meter will be integrated with Medtronic's future BLE enabled insulin pump systems. - The agreement covers all markets where the BLE enabled pumps will be commercialized. BASEL, Switzerland, Feb. 15, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has signed an exclusive partnership agreement with Medtronic plc. Under the terms of the agreement, Roche will develop a dedicated Bluetooth Low Energy (BLE) enabled blood glucose monitoring meter that will communicate with Medtronic's future BLE enabled insulin pump systems. The new meter will be based on Roche's innovative Accu-Chek Guide platform and will be marketed under the name Accu-Chek Guide Link. The exclusive agreement covers all markets where future BLE enabled pumps will be commercialized. The new Accu-Chek Guide platform offers advanced accuracy by delivering tight 10/10 accuracy for more reliable results1. This is especially important for people with diabetes on insulin therapy, as reliable and accurate blood glucose measurements are instrumental in deriving the correct therapy decisions and insulin dosage.2 "We are very excited about this partnership as it will grant people with diabetes broader access to our innovative and highly accurate blood glucose monitoring technology", says Marcel Gmünder, Global Head of Roche Diabetes Care.  "Our partnership with Medtronic is an important next step in bringing our vision to life of helping people with diabetes worry less about their daily therapy routines and experience true relief." References 1 Brazg R., et al. J Diabetes Sci Technol June 2016; Published online before print June 5, DOI: 10.1177/1932296816652902 | 2 Brazg R., et al. J Diabetes Sci Technol 2013;7:144-152 | 3 Ginsberg B., J Diabetes Sci Technol. Jul 2009;3(4):903-913. About Roche Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI). The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. About Roche Diabetes Care Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients' condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. For more information please visit www.accu-chek.com About Accu-Chek Guide The Accu-Chek Guide system is Roche Diabetes Care's new generation of wireless blood glucose monitoring (BGM) systems, designed to respond to previously unmet needs of people with diabetes and their healthcare professionals. As such, it offers new features such as the exclusive, SmartPack spill-resistant strip vial and new test strip chemistry and design. Moreover, the system provides Bluetooth® low energy connectivity to the Accu-Chek Connect diabetes management app and online portal and offers reliable test results that exceed the new global ISO 15197:2013/EN ISO 15197:2015 accuracy standards1,2. 1. Brazg RL, Klaff LJ, Sussmann, AM, Parkin: Accu-Chek Guide Blood Glucose Monitoring System Exceeds International Accuracy Standards, Journal of Diabetes Science and Technology 1–2, DOI: 10.1177/1932296816652902   2 International Organization for Standardization (ISO). ISO 15197:2013. http://www.iso.org/iso/catalogue_detail?csnumber=54976 For more information please contact All trademarks used or mentioned in this release are legally protected.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "United States Diabetes Care Devices Market Outlook to 2022 - Glucose Monitoring and Insulin Delivery" report to their offering. The report provides value, in millions of US dollars and volume (in units) within market categories - Glucose Monitoring and Insulin Delivery. The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is available in the report. Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis. - Annualized market revenues (USD million) and volume (units) data for each of the market categories. Data is provided from 2008 to 2015 and forecast to 2022. - Global corporate-level profiles of key companies operating within the United States Diabetes Care Devices market. Key players covered include LifeScan Inc, Medtronic plc, Bayer HealthCare AG, F. Hoffmann-La Roche Ltd and others. For more information about this report visit http://www.researchandmarkets.com/research/kzgmwm/united_states


The Thyroid Pharmacist, Dr. Isabella Wentz, Pharm.D., FASCP, one of the world’s foremost authorities on the thyroid and thyroid conditions, as well as a proud supporter of ThyroidChange and thyroid activism, has designed and launched a revolutionary new 9-part docuseries titled The Thyroid Secret, which dives deeps into the realities of thyroid disease, dispelling the myths surrounding the condition, and showing individuals a real path to recovery. Dr. Wentz, who graduated from the Midwestern University Chicago College of Pharmacy at the age of 23, has had a storied and successful career including work as a community pharmacist, medication safety pharmacist, and clinical consulting pharmacist. As a Fellow of the American Society of Consultant Pharmacist, Dr. Wentz holds additional certifications in Advanced Diabetes Care, and Medication Therapy Management. About two and a half years into her career as a pharmacist, Dr. Wentz’s health took a turn for the worse. She began suffering from exhaustion, irritable bowel syndrome, carpal tunnel, acid reflux, and debilitating allergies. Eventually, she was diagnosed with Hashimoto’s, and auto-immune thyroid disease. She was told that the only treatment was to take thyroid medications. It was at that moment when Dr. Wentz decided to take her health into her own hands. “I didn’t want to give up. I thought that all my symptoms were somehow connected… There has got to be some lifestyle factors that contributed to this condition! There’s got to be ways I can make myself feel better! There has got to be ways I can help stop the progression… What can I do as a person with this condition to give myself the best possible life?" said Dr. Wentz. After years of researching Hashimoto’s and Hyperthyroidism, Dr. Wentz wrote Hashimoto’s Thyroiditis: Lifestyle Interventions for Finding and Treating the Root Cause. And that was just the beginning of her mission to change the lives of those who suffer from thyroid conditions. Dr. Wentz described this as, “a mission that literally makes me jump out of bed in the morning.” She went on to add, “Putting together The Thyroid Secret documentary series is one of my biggest dreams coming to fruition because I know it will reach so many people with the truth about thyroid disease. Millions of people simply have no idea that they can recover their health from this debilitating condition, and I hope with every part of my being that this film impacts lives in ways I can’t even begin to fathom!” The Thyroid Secret includes the comprehensive 9-part docuseries, exclusive one-on-one interviews with over 100 of the top thyroid experts around the world, and 65 inspiring interview stories in which real patients share the struggles and success with thyroid disease. The life-changing docuseries, The Thyroid Secret, is scheduled for full release on March, 1st, and will be available at thethyroidsecret.com. To learn more about Dr. Isabella Wentz, PharmD, FASCP, visit thyroidpharmacist.com. Visit some of our informational sites as well:


- Roche Diabetes Care desarrollará un medidor de glucosa en sangre mediante conectividad Bluetooth Low Energy (BLE) especial basado en la nueva plataforma Accu-Chek Guide. - Este medidor se integrará con futuros sistemas de bomba de insulina mediante BLE de Medtronic. - El acuerdo...


ARLINGTON, Tenn.--(BUSINESS WIRE)--MicroPort Orthopedics Inc., a medical device company that develops and manufactures cutting edge joint replacement implants designed to help patients achieve full function faster, announced that The Knee has published a study evaluating long-term clinical and radiographic outcomes of the Medial-Pivot Knee System. The results demonstrate excellent clinical outcomes for both satisfaction (95%) and survivorship (98.8%) at 17 years with patients noting a great sense of stability and comfort during regular activities.1 It has been reported that approximately 20% of patients are not satisfied with the outcome of their total knee replacement as a result of residual pain and functional issues often attributed to implant design.2 MicroPort’s Medial-Pivot Knee System is uniquely designed to restore stability and normal knee kinematics to deliver reproducible outcomes that can improve function and drive patient satisfaction. “I am in my third year of using the Evolution® Medial-Pivot Knee System and this publication validates the results that I have seen in my practice,” says David Backstein, MD, MEd, FRCSC, Head of Orthopaedic Surgery at Mount Sinai Hospital in Toronto, Ontario. “In my experience, the functional outcomes for patients treated with this system have certainly been superior than the systems I’ve used in the past and patients have fewer complaints. When I see them at six or eight weeks follow-up, they're at a different stage of recovery than I was seeing previously with traditional implant designs. I've been exceptionally happy with the results and feel comfortable knowing I am implanting a prosthesis with 98.8% survivorship at 17 years.” The paper, titled, A Long Term Clinical Outcome of the Medial Pivot Knee Arthroplasty System was authored by George A Macheras et al. from the “KAT” General Hospital, Athens, Greece. In the study, 325 patients with knee osteoarthritis underwent Total Knee Arthroplasty (TKA) using the Medial-Pivot prosthesis. All patients showed a statistically significant improvement in the Knee Society clinical rating system, Western Ontario and McMaster Universities Osteoarthritis Index, and Oxford knee score. The majority of patients (94%) were able to perform age-appropriate activities with average knee flexion of 120° and 98% of patients reported relief of pain to be excellent, very good or good. Additionally, survival analysis showed a cumulative success rate of 98.8% at 17 years. About MicroPort Orthopedics Established in January 2014, MicroPort Orthopedics Inc. is a multinational producer of orthopedic products and a proud member of the MicroPort Scientific Corporation family of companies. From its headquarters in Arlington, Tennessee, MicroPort Orthopedics develops, produces, and distributes innovative orthopedic reconstructive products. The company’s U.S.-based manufacturing and logistics capabilities deliver high quality hip and knee products to patients and their doctors in over 60 countries, including the U.S., EMEA, Japan, Latin America, and China markets. For more information about MicroPort Orthopedics, visit http://www.ortho.microport.com/. About MicroPort MicroPort Scientific Corporation is a leading medical device company focused on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 20 seconds in thousands of major hospitals around the world, MicroPort maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient-oriented global enterprise that improves and reshapes patient lives through application of innovative science and technology. For more information, please refer to: http://www.microport.com. Forward-Looking Statements Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe,” “intend,” “expect,” “anticipate,” “project,” “estimate,” “predict,” “is confident,” “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China. This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever. 1. George A. Macheras et al. “A long term clinical outcome of the Medial Pivot Knee Arthroplasty System.” The Knee Journal, Published: January 29, 2017. 2. Thambiah, Matthew Dhanaraj et al. “Patient Satisfaction after Total Knee Arthroplasty: An Asian Perspective.” Singapore Medical Journal 56.5 (2015): 259–263. PMC. Web. 22 Feb. 2017.


LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces its post-earnings coverage on Becton, Dickinson and Co. (NYSE: BDX) ("BD"). The Company reported its first quarter fiscal 2017 financial results for the fourth quarter and fiscal on February 01, 2017. The medical technology firm surpassed top- and bottom-line expectation and raised its earnings outlook. Register with us now for your free membership at: One of Becton, Dickinson and Co.'s competitors within the Medical Instruments & Supplies space, The Cooper Companies, Inc. (NYSE: COO), announced on February 01, 2017, that it will release its Q1 2017 financial results on Thursday, March 02, 2017, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. AWS will be initiating a research report on Cooper Cos. a few days following its earnings release. Today, AWS is promoting its earnings coverage on BDX; touching on COO. Get our free coverage by signing up to: For the first fiscal quarter ended December 31, 2016, BD reported quarterly revenues of $2.922 billion, down 2.1% from the prior-year same period revenues, due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, the reported quarter revenues grew 6.1%. BD's revenue figures surpassed analysts' consensus of $2.85 billion. On a performance basis, BD's gross profit margin improved by 190 basis points compared to the year ago same quarter at 54.3%. This growth was driven by continuous improvement initiatives, cost synergies, and favorable mix which include the positive impact of divestitures. On an operating margin basis, the Company delivered an approximately 250 basis points of margin expansion to 23.8%, as it continues to drive cost synergies. In addition, margin expansion was positively impacted by the divestiture of the respiratory solutions business. For Q1 FY17, BD's diluted earnings per share were $2.58 compared to $1.06 in the prior-year comparable period. This represents an increase of 143.4% and is primarily due to a litigation reserve reversal following a favorable appellate antitrust ruling. The Company's adjusted diluted earnings per share were $2.33 in the reported quarter compared to $1.96 in the prior-year same period. This represents an increase in adjusted diluted earnings per share of 18.9%, or 19.4% on a currency-neutral basis. The earning numbers comfortably surpassed Wall Street's expectations of $2.12 per share. During Q1 FY17, in the BD's Medical segment, worldwide revenues totaled $1.964 billion down 4.4% from Q1 FY16 due to the divestiture of the Respiratory Solutions business. On a comparable, currency-neutral basis, revenues increased 7.5%. Performance in the Pharmaceutical Systems and Medication Management Solutions units was positively impacted, in part, by the timing of customer orders and capital placements, respectively, which occurred in Q1 FY17, earlier than the Company initially anticipated. In the BD Life Sciences segment, worldwide revenues for Q1 FY17 were $958 million, an increase of 2.7% over the prior-year comparable period, or an increase of 3.2% on a currency-neutral basis. The segment's revenue growth reflects strong performance in the Diagnostic Systems and Preanalytical Systems units. For Q1 FY17, BD's revenue in the US was $1.63 billion, a decrease of 3.6% from the prior-year same period due to the aforementioned divestiture. On a comparable basis, US revenues increased 5.5%. Within BD's Medical segment, growth was driven by strong performance in the Medication Management Solutions and Diabetes Care units. Growth in BD's Life Sciences segment was driven by solid growth in the Diagnostics Systems unit, and favorable timing of orders in Advanced Bioprocessing in the Biosciences unit. For Q1 FY17, BD's revenues outside of the US of $1.292 billion were about flat when compared with the prior year corresponding period due to the aforementioned divestiture. On a comparable, currency-neutral basis, revenues outside of the US increased 6.8%. For the international region within BD's Medical segment, growth was driven by capital installations in the Medication Management Solutions unit, and strength in the Pharmaceutical Systems unit, which was aided in part by the aforementioned timing of customer orders. Growth in BD's Life Sciences segment reflects sales of safety-engineered products, and strength in Latin America and Asia/Pacific in the Diagnostic Systems unit, including a favorable comparison to the prior-year's same period in China. BD expects FY17 revenues to decrease 3.5% to 4.0%, down compared to the previously issued guidance of a decrease of 3.0% to 3.5% due to the incrementally negative estimated impact from foreign currency. The Company continues to estimate that revenues for FY17 will increase 4.5% to 5.0% on a comparable, currency-neutral basis. The Company now expects FY17 diluted earnings per share to be between $7.90 and $8.00, which represents growth of approximately 76.0% to 78.0%. On a currency-neutral basis, the Company is raising FY17 adjusted diluted earnings per share to $9.70 to $9.80, which represents growth of 13.0% to 14.0% including an estimated 1.5% of dilution related to the Respiratory Solutions divestiture. This is an increase from previously issued guidance of $9.62 to $9.72, which represented approximately 12.0% to 13.0 % growth. On February 15, 2017, Becton, Dickinson and Co.'s share price finished the trading session at $180.09, slightly advancing 0.74%. A total volume of 855.05 thousand shares exchanged hands. The stock has advanced 3.85% and 27.05% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 8.78%. The stock is trading at a PE ratio of 29.93 and has a dividend yield of 1.62%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces its post-earnings coverage on Becton, Dickinson and Co. (NYSE: BDX) ("BD"). The Company reported its first quarter fiscal 2017 financial results for the fourth quarter and fiscal on February 01, 2017. The medical technology firm surpassed top- and bottom-line expectation and raised its earnings outlook. Register with us now for your free membership at: One of Becton, Dickinson and Co.'s competitors within the Medical Instruments & Supplies space, The Cooper Companies, Inc. (NYSE: COO), announced on February 01, 2017, that it will release its Q1 2017 financial results on Thursday, March 02, 2017, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. AWS will be initiating a research report on Cooper Cos. a few days following its earnings release. Today, AWS is promoting its earnings coverage on BDX; touching on COO. Get our free coverage by signing up to: For the first fiscal quarter ended December 31, 2016, BD reported quarterly revenues of $2.922 billion, down 2.1% from the prior-year same period revenues, due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, the reported quarter revenues grew 6.1%. BD's revenue figures surpassed analysts' consensus of $2.85 billion. On a performance basis, BD's gross profit margin improved by 190 basis points compared to the year ago same quarter at 54.3%. This growth was driven by continuous improvement initiatives, cost synergies, and favorable mix which include the positive impact of divestitures. On an operating margin basis, the Company delivered an approximately 250 basis points of margin expansion to 23.8%, as it continues to drive cost synergies. In addition, margin expansion was positively impacted by the divestiture of the respiratory solutions business. For Q1 FY17, BD's diluted earnings per share were $2.58 compared to $1.06 in the prior-year comparable period. This represents an increase of 143.4% and is primarily due to a litigation reserve reversal following a favorable appellate antitrust ruling. The Company's adjusted diluted earnings per share were $2.33 in the reported quarter compared to $1.96 in the prior-year same period. This represents an increase in adjusted diluted earnings per share of 18.9%, or 19.4% on a currency-neutral basis. The earning numbers comfortably surpassed Wall Street's expectations of $2.12 per share. During Q1 FY17, in the BD's Medical segment, worldwide revenues totaled $1.964 billion down 4.4% from Q1 FY16 due to the divestiture of the Respiratory Solutions business. On a comparable, currency-neutral basis, revenues increased 7.5%. Performance in the Pharmaceutical Systems and Medication Management Solutions units was positively impacted, in part, by the timing of customer orders and capital placements, respectively, which occurred in Q1 FY17, earlier than the Company initially anticipated. In the BD Life Sciences segment, worldwide revenues for Q1 FY17 were $958 million, an increase of 2.7% over the prior-year comparable period, or an increase of 3.2% on a currency-neutral basis. The segment's revenue growth reflects strong performance in the Diagnostic Systems and Preanalytical Systems units. For Q1 FY17, BD's revenue in the US was $1.63 billion, a decrease of 3.6% from the prior-year same period due to the aforementioned divestiture. On a comparable basis, US revenues increased 5.5%. Within BD's Medical segment, growth was driven by strong performance in the Medication Management Solutions and Diabetes Care units. Growth in BD's Life Sciences segment was driven by solid growth in the Diagnostics Systems unit, and favorable timing of orders in Advanced Bioprocessing in the Biosciences unit. For Q1 FY17, BD's revenues outside of the US of $1.292 billion were about flat when compared with the prior year corresponding period due to the aforementioned divestiture. On a comparable, currency-neutral basis, revenues outside of the US increased 6.8%. For the international region within BD's Medical segment, growth was driven by capital installations in the Medication Management Solutions unit, and strength in the Pharmaceutical Systems unit, which was aided in part by the aforementioned timing of customer orders. Growth in BD's Life Sciences segment reflects sales of safety-engineered products, and strength in Latin America and Asia/Pacific in the Diagnostic Systems unit, including a favorable comparison to the prior-year's same period in China. BD expects FY17 revenues to decrease 3.5% to 4.0%, down compared to the previously issued guidance of a decrease of 3.0% to 3.5% due to the incrementally negative estimated impact from foreign currency. The Company continues to estimate that revenues for FY17 will increase 4.5% to 5.0% on a comparable, currency-neutral basis. The Company now expects FY17 diluted earnings per share to be between $7.90 and $8.00, which represents growth of approximately 76.0% to 78.0%. On a currency-neutral basis, the Company is raising FY17 adjusted diluted earnings per share to $9.70 to $9.80, which represents growth of 13.0% to 14.0% including an estimated 1.5% of dilution related to the Respiratory Solutions divestiture. This is an increase from previously issued guidance of $9.62 to $9.72, which represented approximately 12.0% to 13.0 % growth. On February 15, 2017, Becton, Dickinson and Co.'s share price finished the trading session at $180.09, slightly advancing 0.74%. A total volume of 855.05 thousand shares exchanged hands. The stock has advanced 3.85% and 27.05% in the last month and past twelve months, respectively. Furthermore, since the start of the year, shares of the Company have gained 8.78%. The stock is trading at a PE ratio of 29.93 and has a dividend yield of 1.62%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Loading Diabetes Care collaborators
Loading Diabetes Care collaborators